← Evidence map

TrialAntimicrobial agents and chemotherapy2005

Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children.

Ram Yogev et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

2 papers cite it

2005

2006

2007

2008

2009

2010

2011

this papercites it

Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children. | OpenQuestion